Search Results

Advanced Development of Additive Manufacturing ( A.D.A.M. ), a provider of 3D printing systems for customized bone implants, and the Icahn School of Medicine at Mount Sinai , in New York, NY , a renowned educational and health institution, have established a collaboration, which aims to enhance healthcare by innovating in bone implant delivery and soft tissue medical device development.

Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence -powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced the closing of its license agreements with the Icahn School of Medicine at Mount Sinai, in New York, NY, to develop and commercialize electrocardiographic AI algorithms and assets.

Caris Life Sciences® announced that the Icahn School of Medicine at Mount Sinai, in New York, NY, has joined the Caris Precision Oncology Alliance™ and will collaborate with Caris on various research projects.

In a study published online in CELL , scientists at UCSF QBI, University College London and the Icahn School of Medicine at Mount Sinai reported breakthrough findings on convergent evolutionary mechanisms shared by COVID-19 variants, allowing them to overcome both adaptive and innate immune system barriers.

Adding a new indication for the CAR T cell therapy could help BMS offset the loss-of-exclusivity headwinds it faces in the coming years.

Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai recently announced the creation of the Center for Engineering and Precision Medicine, one of the first centers in the nation to bridge engineering and engineering science with medicine.

Brain–computer interface company Precision Neuroscience Corporation announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania.

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular benefits in the world’s fastest-growing drug class.

Linus Biotechnology Inc. and Mount Sinai Innovation Partners announced an exclusive worldwide license and collaboration agreement in progress with the Icahn School of Medicine at Mount Sinai, the medical school of the Mount Sinai Health System.